Stephen Ray Mitchell Sells 7,000 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Stock

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Get Free Report) Director Stephen Ray Mitchell sold 7,000 shares of the stock in a transaction that occurred on Friday, June 13th. The shares were sold at an average price of $4.59, for a total transaction of $32,130.00. Following the completion of the transaction, the director now owns 97,082 shares in the company, valued at $445,606.38. This represents a 6.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Vanda Pharmaceuticals Stock Performance

NASDAQ:VNDA traded down $0.02 during trading hours on Friday, hitting $4.51. The stock had a trading volume of 308,335 shares, compared to its average volume of 631,552. The business's 50 day moving average is $4.36 and its 200-day moving average is $4.54. The company has a market cap of $265.79 million, a price-to-earnings ratio of -6.01 and a beta of 0.66. Vanda Pharmaceuticals Inc. has a one year low of $3.81 and a one year high of $6.37.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.05. The company had revenue of $50.04 million during the quarter, compared to analyst estimates of $45.13 million. Vanda Pharmaceuticals had a negative net margin of 21.98% and a negative return on equity of 8.30%. On average, sell-side analysts anticipate that Vanda Pharmaceuticals Inc. will post -1.12 EPS for the current fiscal year.

Institutional Investors Weigh In On Vanda Pharmaceuticals

Large investors have recently modified their holdings of the business. Quantinno Capital Management LP acquired a new position in shares of Vanda Pharmaceuticals in the 4th quarter valued at approximately $48,000. PVG Asset Management Corp bought a new position in Vanda Pharmaceuticals in the first quarter valued at approximately $48,000. Linden Thomas Advisory Services LLC acquired a new position in shares of Vanda Pharmaceuticals in the first quarter valued at approximately $49,000. Nations Financial Group Inc. IA ADV acquired a new position in shares of Vanda Pharmaceuticals in the first quarter valued at approximately $67,000. Finally, XTX Topco Ltd bought a new stake in shares of Vanda Pharmaceuticals during the fourth quarter worth $69,000. 88.14% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on VNDA. HC Wainwright reissued a "buy" rating and issued a $20.00 price target on shares of Vanda Pharmaceuticals in a research note on Wednesday, May 7th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $13.00 price objective on shares of Vanda Pharmaceuticals in a report on Wednesday, May 14th. Finally, Wall Street Zen upgraded Vanda Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday, June 14th.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.